Brief: Mei Pharma And Kyowa Kirin Announce Data From Ongoing Global Phase 2 Tidal Study Evaluating Zandelisib As A Single Agent In Patients With Relapsed Or Refractory Follicular Lymphoma

Kyowa Kirin

30/11/2021 12:57

Nov 30 (Reuters) - Kyowa Kirin Co Ltd  4151.T :
    * MEI PHARMA AND KYOWA KIRIN ANNOUNCE DATA FROM ONGOING
GLOBAL
PHASE 2 TIDAL STUDY EVALUATING ZANDELISIB AS A SINGLE AGENT IN
PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
    * MEI PHARMA INC - ZANDELISIB DEMONSTRATED 70.3% OBJECTIVE
RESPONSE RATE; 35.2% ACHIEVED COMPLETE RESPONSE
    * MEI PHARMA INC - 9.9% OF PATIENTS DISCONTINUED THERAPY DUE
TO A
DRUG RELATED ADVERSE EVENT
    * MEI PHARMA INC - IN LINE WITH PREVIOUSLY REPORTED DATA
FROM
PHASE 1B STUDY, ZANDELISIB WAS GENERALLY WELL TOLERATED
    * MEI PHARMA INC - PATIENTS ENROLLED IN STUDY WILL CONTINUE
TO BE
FOLLOWED FOR SAFETY AND DOR


Further company coverage:  4151.T 

 ((Reuters.Briefs@thomsonreuters.com;))